A Pilot, Single-Blinded, Randomized Crossover Trial of Cramp Reduction with Angiotensin II in Maintenance Patients on Hemodialysis (the CRAMP-HD Study)

What Was Tested

This randomized controlled trial paper looks at Angiotensin II.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

The researchers performed a pilot, single-blinded, randomized crossover trial of patients receiving IHD who frequently experience intradialytic muscle cramps.

Patients were randomly allocated to receive either intravenous angiotensin II or placebo for the duration of their first dialysis session of the week.

How the Study Was Run

In design terms this was a randomized, single-blind, placebo-controlled, crossover and pilot study.

The participants were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.

Only one side, usually the participants, was kept unaware of whether Angiotensin II was given.

Some participants received a placebo instead of Angiotensin II, giving a reference point.

In the crossover set-up each of the participants took both Angiotensin II and the comparison in turn, acting as their own control.

A time span of 4 weeks appears in the methods.

They crossed over to the alternate arm each week for 4 weeks.

The primary outcome was safety.

Secondary outcomes included cramp-related symptoms, hemodynamic parameters, dialysis prescription alterations, and biomarkers.

What Was Measured

Topics PubMed links to this paper include Angiotensin II, Pilot Projects, Renal Dialysis, Muscle Cramp, Kidney Failure, Chronic and Vasoconstrictor Agents.

Author keywords: Blood pressure, Cramps, Hemodialysis and Renin.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Angiotensin II over 4 weeks.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (American journal of nephrology), a journal based in Switzerland.

More context: the Angiotensin II compound page, all human trials.